Knowledge-care gaps persist in #HF: among 2588 patients with #HFrEF in the CHAMP-HF registry (@sjgreene_md @javedbutler1), a minority of eligible patients were treated with target doses of evidence-informed #HF meds. https://t.co/XnbtVKvRNo
RT @gcfmd: Critical target for clinician education, quality improvement, and actionable patient-centered metrics. Hundreds of thousands of…
RT @gcfmd: Critical target for clinician education, quality improvement, and actionable patient-centered metrics. Hundreds of thousands of…
RT @JACCJournals: Majority of eligible #HFrEF pts don't receive target doses of med. therapy at any point. In an #ACC19 poster, published i…
RT @SJGreene_md: In current US practice, major gaps in outpatient titration of HFrEF medical therapy. Few eligible pts ever receive target…
Amazingly this simple deficit justifies the field of advanced heart failure. No one does this better than us @ishlt @HFSA
RT @SJGreene_md: In current US practice, major gaps in outpatient titration of HFrEF medical therapy. Few eligible pts ever receive target…
RT @SJGreene_md: In current US practice, major gaps in outpatient titration of HFrEF medical therapy. Few eligible pts ever receive target…
RT @SJGreene_md: In current US practice, major gaps in outpatient titration of HFrEF medical therapy. Few eligible pts ever receive target…
RT @gcfmd: Critical target for clinician education, quality improvement, and actionable patient-centered metrics. Hundreds of thousands of…
RT @JACCJournals: Majority of eligible #HFrEF pts don't receive target doses of med. therapy at any point. In an #ACC19 poster, published i…
In current US practice, major gaps in outpatient titration of HFrEF medical therapy. Few eligible pts ever receive target doses. Critical opportunities to improve use of GDMT & outcomes. New in @JACCJournals w/ #ACC19 https://t.co/fLaRzFVbSm @Javed
RT @gcfmd: Critical target for clinician education, quality improvement, and actionable patient-centered metrics. Hundreds of thousands of…
RT @JACCJournals: Majority of eligible #HFrEF pts don't receive target doses of med. therapy at any point. In an #ACC19 poster, published i…
Yikes! And I’m certain this is true in the CV clinics as well. A point well made by mentor @JJheart_doc during our morning reports! Cc: @NjambiM_MD @NinoNJ @goosecoid @IAmDrIbrahim
RT @JACCJournals: Majority of eligible #HFrEF pts don't receive target doses of med. therapy at any point. In an #ACC19 poster, published i…
RT @gcfmd: Critical target for clinician education, quality improvement, and actionable patient-centered metrics. Hundreds of thousands of…
RT @JACCJournals: Majority of eligible #HFrEF pts don't receive target doses of med. therapy at any point. In an #ACC19 poster, published i…
Critical target for clinician education, quality improvement, and actionable patient-centered metrics. Hundreds of thousands of preventable events in HFrEF could be averted with optimal implementation. @rcstarling @coconnormd @MinnowWalsh @JJheart_doc @jes
RT @JACCJournals: Majority of eligible #HFrEF pts don't receive target doses of med. therapy at any point. In an #ACC19 poster, published i…
RT @JACCJournals: Majority of eligible #HFrEF pts don't receive target doses of med. therapy at any point. In an #ACC19 poster, published i…
RT @JACCJournals: Majority of eligible #HFrEF pts don't receive target doses of med. therapy at any point. In an #ACC19 poster, published i…
RT @JACCJournals: Majority of eligible #HFrEF pts don't receive target doses of med. therapy at any point. In an #ACC19 poster, published i…
We need to push for EBM supported target treatment of #HFrEF
RT @JACCJournals: Majority of eligible #HFrEF pts don't receive target doses of med. therapy at any point. In an #ACC19 poster, published i…
RT @JACCJournals: Majority of eligible #HFrEF pts don't receive target doses of med. therapy at any point. In an #ACC19 poster, published i…
RT @JACCJournals: Majority of eligible #HFrEF pts don't receive target doses of med. therapy at any point. In an #ACC19 poster, published i…
RT @JACCJournals: Majority of eligible #HFrEF pts don't receive target doses of med. therapy at any point. In an #ACC19 poster, published i…
RT @JACCJournals: Majority of eligible #HFrEF pts don't receive target doses of med. therapy at any point. In an #ACC19 poster, published i…
RT @JACCJournals: Majority of eligible #HFrEF pts don't receive target doses of med. therapy at any point. In an #ACC19 poster, published i…
RT @JACCJournals: Majority of eligible #HFrEF pts don't receive target doses of med. therapy at any point. In an #ACC19 poster, published i…
RT @JACCJournals: Majority of eligible #HFrEF pts don't receive target doses of med. therapy at any point. In an #ACC19 poster, published i…
RT @JACCJournals: Majority of eligible #HFrEF pts don't receive target doses of med. therapy at any point. In an #ACC19 poster, published i…
RT @JACCJournals: Majority of eligible #HFrEF pts don't receive target doses of med. therapy at any point. In an #ACC19 poster, published i…
Majority of eligible #HFrEF pts don't receive target doses of med. therapy at any point. In an #ACC19 poster, published in #JACC, @SJGreene_md, @JavedButler1 et al. state further efforts "urgently” needed to improve guideline-directed med. titration. https
We can do better for our HFrEF patients! https://t.co/Hb4wuvLEz9 https://t.co/79wLZazv6r
CHAMP-HFレジストリーにおいて、大多数のHFrEF患者が、ACEI、ARB、ARNI、BB、MRAの目標用量を投与されていなかった。 https://t.co/oanU1ArhoV
Editors' Insights: Majority of eligible HFrEF patients do not receive target doses of medical therapy at any point, and use of each guideline-directed therapy falls below 75%.#JACC: further quality improvement efforts are “urgently” needed. https://t.co/BA